Friday, June 07, 2024 9:07:49 PM
For the quarterly period ended March 31, 2024
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000792935/000190359624000371/grst_10q.htm
Revolving line of credit
On February 1, 2024 Ethema Health Corporation, American Treatment Holdings Inc, and Evernia Health Center LLC entered into a secured revolving line of credit agreement (“ Agreement”) with Testing 123, LLC. The draw under the is limited to a maximum of 80% of the Receivables balance as provided to the Lender, subject to the maximum borrowing under the Term Loan Agreement of $1,000,000. The interest on the term loan is 5% per month. The revolving credit line is valid for a period of two years and each draw will have a maturity date that is two years from the draw date, with an origination fee of $1,000 per draw. Each loan may be prepaid at any time without penalty. The Company will pay a commitment fee of $40,000 to the borrower in common shares on the completion of a public offering, unless no such offering takes place within a year, whereby the outstanding principal will be increased by $40,000. The revolving credit line is secured by all assets, tangible and intangible of the Company and its direct and indirect subsidiaries, American Treatment Holdings, Inc. and Evernia Health Center, LLC.
Page 24
17. Subsequent events
Revolving line of credit
Between April 8, 2024 and May 2, 2024, the Company repaid $186,120 of principal and interest on the initial revolving line of credit advance on February 1, 2024.
On May 15, 2024, the Company drew down a further $130,000 on the revolving line of credit, of which $85,800 was used to repay the second line of credit advance on February 15, 2024, the balance of $44,200 was used for working capital purposes.
Everything that I post is just my informed opinion and is simply an invitation to debate. Trade on your own due diligence please..
Recent GRST News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/23/2024 01:21:05 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 10:19:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 07:59:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:46:15 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 07:23:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 05:40:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 05:39:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:25:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/11/2024 06:20:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 02:47:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/31/2024 08:27:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/07/2024 08:16:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
Consumer Automotive Finance, Inc. Announces Cancellation of 200 Million Common Shares and Updates on Name and Ticker Symbol Change • CAFI • Dec 6, 2024 12:45 PM
4Cable TV International, Inc. (OTC.PK: CATV) Signs Letter of Intent to Acquire MariJ Pharmaceuticals from Branded Legacy, Inc. and Retains New Counsel for Name Change with FINRA • CATV • Dec 6, 2024 8:00 AM
Bantec's Howco Distributing Co. and Bantec Environmental Corp. Win Contracts • BANT • Dec 5, 2024 10:00 AM
Kona Gold Beverage, Inc. Announces Strategic Reorganization and a Bold New Direction • KGKG • Dec 5, 2024 9:33 AM
Branded Legacy, Inc. Strengthens Biotech Leadership, Focuses on Expansion, and Advances Strategic Rebranding • BLEG • Dec 5, 2024 8:30 AM
Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy • AVAI • Dec 4, 2024 8:00 AM